Related Experiment Video
Updated: May 13, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
A fatal case of fulminant neuroleptic malignant syndrome: A case report
Hitomi Komoriya1, Konoka Nomura1, Toshinori Shirata1
1Department of Psychiatry Yamagata University School of Medicine Yamagata Japan.
Background:
Neuroleptic malignant syndrome (NMS), a rare but potentially life-threatening adverse reaction to treatment with antipsychotic drugs, is characterized by hyperthermia, muscle rigidity, impaired consciousness, and autonomic disturbances. Some reports have described rapidly progressing cases of NMS resulting in death within several days. This report describes a clinical course of fatal and fulminant NMS in a patient with schizoaffective disorder.
Case Presentation:
A 67-year-old man had long been in a stable condition under antipsychotic pharmacotherapy. At 3 days before admission to our hospital, he complained of diarrhea, fatigue, and reduced appetite. On admission to our hospital, he showed fever, mild muscle rigidity at the four extremities, elevated heart rate, hypertension, excessive diaphoresis, and decreased percutaneous oxygen saturation (SpO2). He was diagnosed as having NMS. Within 3 days after the onset of NMS, he displayed severe hyperthermia up to 41.4°C and severe autonomic disturbances, including elevated heart rate and hypertension. Despite treatments with dantrolene and bromocriptine, he went into shock and died on the fourth day after admission.
Conclusion:
The present case suggests that severe hyperthermia and severe autonomic disturbances at the early stage of the onset might be signs of fatal and fulminant NMS. It may be recommended that clinicians consider electro-convulsive therapy when treating fulminant NMS with these symptoms.
Insights
Neuroleptic malignant syndrome (NMS) is a rare, severe reaction to antipsychotics. Early signs like high fever and autonomic instability may indicate a fatal course, suggesting prompt intervention is critical.
Area of Science:
- Pharmacology
- Neurology
- Critical Care Medicine
Background:
- Neuroleptic malignant syndrome (NMS) is a rare, life-threatening adverse drug reaction associated with antipsychotic medications.
- It is characterized by hyperthermia, muscle rigidity, altered mental status, and autonomic dysfunction.
- Rapidly progressing NMS can be fatal within days.
Observation:
- A 67-year-old male with schizoaffective disorder developed NMS during antipsychotic pharmacotherapy.
- Initial symptoms included fever, muscle rigidity, tachycardia, hypertension, and hypoxia.
- The patient rapidly progressed to severe hyperthermia (41.4°C) and autonomic instability despite treatment with dantrolene and bromocriptine.
Findings:
- The patient experienced shock and died on the fourth day after admission.
- Fulminant NMS was confirmed post-mortem.
- Early severe hyperthermia and autonomic disturbances were identified as potential indicators of a fatal outcome.
Implications:
- Severe hyperthermia and autonomic disturbances in early NMS onset may predict a fulminant and fatal course.
- Clinicians should consider electroconvulsive therapy (ECT) for fulminant NMS presenting with these severe early symptoms.
Related Concept Videos
Pharmaceutical Poisoning: Potential Scenarios
Viral Meningitis
Bacterial Meningitis I: Introduction
Encephalitis l: Introduction
Multiple Sclerosis l: Introduction
Huntington Disease l: Introduction

